Asset Details
Do you wish to reserve the book?
Tumor-Directed Therapeutic Targets in Cushing Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tumor-Directed Therapeutic Targets in Cushing Disease
Do you wish to request the book?
Tumor-Directed Therapeutic Targets in Cushing Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tumor-Directed Therapeutic Targets in Cushing Disease
2019
Overview
The most frequent cause of endogenous hypercortisolism is Cushing disease (CD), a devastating condition associated with severe comorbidities and high mortality. Effective tumor-targeting therapeutics are limited.
Search in PubMed with key words \"corticotroph\" and \"Cushing's disease\" plus the name of the mentioned therapeutic agent and in associated references of the obtained papers. Additionally, potential therapeutics were obtained from ClinicalTrials.gov with a search for \"Cushing disease.\"
At present, the tumor-targeted pharmacological therapy of CD is concentrated on dopamine agonists (cabergoline) and somatostatin analogs (pasireotide) with varying efficacy, escape from response, and considerable side effects. Preclinical studies on corticotroph pathophysiology have brought forward potential drugs such as retinoic acid, silibinin, and roscovitine, whose efficacy and safety remain to be determined.
For many patients with CD, effective tumor-targeted pharmacological therapy is still lacking. Coordinated efforts are pivotal in establishing efficacy and safety of novel therapeutics in this rare but devastating disease.
Publisher
Copyright Oxford University Press,Oxford University Press
Subject
/ ACTH-Secreting Pituitary Adenoma - complications
/ ACTH-Secreting Pituitary Adenoma - drug therapy
/ ACTH-Secreting Pituitary Adenoma - pathology
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Cabergoline - therapeutic use
/ Corticotrophs - drug effects
/ Dopamine
/ Hormones
/ Humans
/ Materia medica and therapeutics
/ Pituitary ACTH Hypersecretion - drug therapy
/ Pituitary ACTH Hypersecretion - etiology
/ Pituitary ACTH Hypersecretion - pathology
/ Roscovitine - therapeutic use
/ Somatostatin - analogs & derivatives
/ Somatostatin - therapeutic use
/ Tumors
